TD Waterhouse Canada Inc. Trims Stake in Zimmer Biomet Holdings, Inc. $ZBH

TD Waterhouse Canada Inc. decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 48.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,109 shares of the medical equipment provider’s stock after selling 5,766 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Zimmer Biomet were worth $514,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZBH. OMERS ADMINISTRATION Corp purchased a new stake in shares of Zimmer Biomet during the second quarter valued at $922,000. Hsbc Holdings PLC purchased a new stake in Zimmer Biomet in the 2nd quarter valued at about $35,417,000. PNC Financial Services Group Inc. grew its stake in Zimmer Biomet by 9.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock worth $14,495,000 after acquiring an additional 13,883 shares in the last quarter. Morningstar Investment Management LLC increased its position in shares of Zimmer Biomet by 235.4% during the fourth quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock worth $5,204,000 after acquiring an additional 40,610 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of Zimmer Biomet by 257.2% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock valued at $3,091,000 after acquiring an additional 24,748 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Down 2.4%

Shares of Zimmer Biomet stock opened at $92.30 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The company has a market cap of $17.61 billion, a P/E ratio of 22.46, a PEG ratio of 1.79 and a beta of 0.47. The firm’s 50 day moving average price is $95.42 and its 200-day moving average price is $91.51. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $106.88.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. During the same quarter in the prior year, the company posted $2.07 earnings per share. Zimmer Biomet’s revenue for the quarter was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ZBH shares. Royal Bank Of Canada raised their price objective on Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. UBS Group restated a “buy” rating and issued a $120.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Finally, Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $104.42.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares of the company’s stock, valued at $6,415,468.85. This trade represents a 4.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.28% of the stock is owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.